3RD CARDIOGENIC SHOCK WORKSHOP

OPTIMAL COMBINATION OF PHARMACOLOGICAL AGENTS & DEVICES IN CARDIOGENIC SHOCK:
ESCALATION AND DE-ESCALATION

French Embassy, Washington DC • Thursday, June 23, 2022

SCIENTIFIC PROGRAM

8:00 AM  Welcome coffee


8:40 AM  SESSION 1: NOVELTIES IN CARDIOGENIC SHOCK DEFINITION/CLASSIFICATION
Co-Chairs: A Sionis (Barcelona, ES), S Price (London, UK)

SHARC: M Krucoff (Durham, US) 📚.
Subphenotypes of Cardiogenic Shock: P Lawler (Toronto, CA)
Demographics in acute myocardial infarction-cardiogenic shock: L Ya’Qoub (Detroit, US) 📚.
Few improvements over decades: N Aissaoui (Paris, FR) 📚.
Informed consent in the US: C WU (FDA, US) 📚.
Launch of the AHA Cardiogenic Shock Registry: D Morrow (Boston, US)
Towards a European CS registry: A Proudfoot (London, UK) 📚.
Discussion: J Jentzer (Rochester MN, US)

10:30 AM  Coffee Break

10:45 AM  SESSION 2: REAL WORLD EXPERIENCE: ES-/DE-ESCALATION INTEGRATION OF PHARMACOLOGY & DEVICES

Session introduction: N Kapur (Boston, US) 📚.

PART A: ESCALATION / DE-ESCALATION IN DRUG THERAPIES
Co-Chairs: H Schaubroeck (Ghent, BE) & S Van Diepen (Edmonton, CA) 📚.

DOREMI trial: B Hibbert (Ottawa, CA)
Angiotensin-2: A Herpain (Brussels, BE)
ACCOST-HF: M Karakas (Hamburg, DE)
Biotherapies: K Bourgeois (4TEEN4, DE)
IV cangrelor STEMI shock: W O’Neill (Detroit, US) 📚.
Refractory shock: M Arrigo (Zurich, CH) 📚.
Panel discussion
SESSION 2, PART B: ESCALATION / DE-ESCALATION COMBO DRUGS & DEVICES

Co-Chairs: M Arrigo (Zurich, CH) & N Gillette (FDA, USA)

ECMO After surgery: P Le Prince (Paris, FR)
ECMO After cardiac arrest: D Yannopoulos (Minneapolis, US)
HYPO-ECMO: B Levy (Nancy, FR)
ECPELLA: A Truesdell (Falls Church, US)
Panel discussion

1:30 PM Lunch Break

SESSION 2, PART C: ONGOING TRIALS: WHAT STANDARD OF ES-/DESESCALATION?

RAPID FIRE SESSION: SHORT PRE-RECORDED PRESENTATIONS

Co-Chairs: U Zeymer (Ludwigschafen, DE) & C Rosner (Falls Church, US)

COCCA: A Dessap (Paris, FR)
DANGER: J Møller (Odense, DN)
ECLS Shock: H Thiele (Liepzig, DE)
Recover-IV: W O’Neill (Detroit, US)
PACCS trial: N Kapur (Boston, US)
ISO-SHOCK: SuperSaturated Oxygen: MB Basir (Detroit, US)
SEISMiC: A Mebazaa (Paris, FR)
Discussants & key messages: P Lawler (Toronto, CA) & C Vandenbriele (Leuven, BE)

Coffee Break

SESSION 3: HOW DOES THE FUTURE LOOK FOR THE MANAGEMENT OF CS?

ROUNDTABLE SESSION


Patient perspective: R Monroe (Charlotte, US)
Industry perspective: J Meikle (Getinge, US)
Industry perspective: C Simonton (Abiomed, US)
Industry perspective: A Bergmann (4TEEN4, DE)
NIH perspective: Y Rosenberg (NIH, US)
FDA perspective: M Moscucci (FDA, US)
EMEA perspective: M Kostrubiec (EMA, PL)
Editor’s perspective: The Lancet Respiratory Medicine Journal: S Spencer (London, UK)
Editor’s perspective: European Heart Journal: S Price (London, UK)
Discussion: J Katz (Durham, US) & D Baran (Norfolk, US)

Adjourn